These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 31152572)

  • 1. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center.
    Araujo KG; Jales RM; Pereira PN; Yoshida A; de Angelo Andrade L; Sarian LO; Derchain S
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):778-783. PubMed ID: 27194129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China.
    He P; Wang JJ; Duan W; Song C; Yang Y; Wu QQ
    J Ovarian Res; 2021 Dec; 14(1):169. PubMed ID: 34857005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods.
    Meys EMJ; Jeelof LS; Achten NMJ; Slangen BFM; Lambrechts S; Kruitwagen RFPM; Van Gorp T
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):784-792. PubMed ID: 27514486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer.
    Pozzati F; Sassu CM; Marini G; Mascilini F; Biscione A; Giannarelli D; Garganese G; Fragomeni SM; Scambia G; Testa AC; Moro F
    Ultrasound Obstet Gynecol; 2023 Oct; 62(4):594-602. PubMed ID: 37204769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women.
    Hiett AK; Sonek JD; Guy M; Reid TJ
    Ultrasound Obstet Gynecol; 2022 May; 59(5):668-676. PubMed ID: 34533862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX: a Portuguese multicenter study.
    Borges AL; Brito M; Ambrósio P; Condeço R; Pinto P; Ambrósio B; Mahomed F; Gama JMR; Bernardo MJ; Gouveia AI; Djokovic D
    Ultrasound Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38477149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability of IOTA score and ADNEX model in the screening of ovarian malignancy in postmenopausal women.
    Nohuz E; De Simone L; Chêne G
    J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):103-107. PubMed ID: 29709594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort.
    Yoeli-Bik R; Longman RE; Wroblewski K; Weigert M; Abramowicz JS; Lengyel E
    JAMA Netw Open; 2023 Jul; 6(7):e2323289. PubMed ID: 37440228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the IOTA ADNEX model performed by two independent gynecologic centers.
    Szubert S; Wojtowicz A; Moszynski R; Zywica P; Dyczkowski K; Stachowiak A; Sajdak S; Szpurek D; Alcazar JL
    Gynecol Oncol; 2016 Sep; 142(3):490-5. PubMed ID: 27374142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort.
    Landolfo C; Bourne T; Froyman W; Van Calster B; Ceusters J; Testa AC; Wynants L; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Savelli L; Fischerova D; Czekierdowski A; Kaijser J; Coosemans A; Scambia G; Vergote I; Timmerman D; Valentin L
    Ultrasound Obstet Gynecol; 2023 Feb; 61(2):231-242. PubMed ID: 36178788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative Evaluation of the ADNEX Model for the Prediction of the Ovarian Cancer Risk of Adnexal Masses at Siriraj Hospital.
    Poonyakanok V; Tanmahasamut P; Jaishuen A; Wongwananuruk T; Asumpinwong C; Panichyawat N; Chantrapanichkul P
    Gynecol Obstet Invest; 2021; 86(1-2):132-138. PubMed ID: 33596584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-Step Strategy for Optimizing the Preoperative Classification of Adnexal Masses in a University Hospital, Using International Ovarian Tumor Analysis Models: Simple Rules and Assessment of Different NEoplasias in the adneXa Model.
    Esquivel Villabona AL; Rodríguez JN; Ayala N; Buriticá C; Gómez AC; Velandia AM; Rodríguez N; Alcázar JL
    J Ultrasound Med; 2022 Feb; 41(2):471-482. PubMed ID: 33890698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of IOTA Simple Rules, IOTA ADNEX Model, RMI, and Subjective Assessment for Preoperative Adnexal Mass Evaluation: The Experience of a Tertiary Care Referral Hospital.
    Vilendecic Z; Radojevic M; Stefanovic K; Dotlic J; Likic Ladjevic I; Dugalic S; Stefanovic A
    Gynecol Obstet Invest; 2023; 88(2):116-122. PubMed ID: 36716716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses.
    Di Legge A; Testa AC; Ameye L; Van Calster B; Lissoni AA; Leone FP; Savelli L; Franchi D; Czekierdowski A; Trio D; Van Holsbeke C; Ferrazzi E; Scambia G; Timmerman D; Valentin L
    Ultrasound Obstet Gynecol; 2012 Sep; 40(3):345-54. PubMed ID: 22611001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective comparative trial comparing O-RADS, IOTA ADNEX model, and RMI score for preoperative evaluation of adnexal masses for prediction of ovarian cancer.
    Poonyakanok V; Tanmahasamut P; Jaishuen A
    J Obstet Gynaecol Res; 2023 May; 49(5):1412-1417. PubMed ID: 36895122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ADNEX model to triage adnexal masses: An external validation study and comparison with the IOTA two-step strategy and subjective assessment by an experienced ultrasound operator.
    Viora E; Piovano E; Baima Poma C; Cotrino I; Castiglione A; Cavallero C; Sciarrone A; Bastonero S; Iskra L; Zola P
    Eur J Obstet Gynecol Reprod Biol; 2020 Apr; 247():207-211. PubMed ID: 32146226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study.
    Van Calster B; Van Hoorde K; Valentin L; Testa AC; Fischerova D; Van Holsbeke C; Savelli L; Franchi D; Epstein E; Kaijser J; Van Belle V; Czekierdowski A; Guerriero S; Fruscio R; Lanzani C; Scala F; Bourne T; Timmerman D;
    BMJ; 2014 Oct; 349():g5920. PubMed ID: 25320247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnexal masses and retrospective assessment of alternative two-step strategy using simple-rules risk.
    Hidalgo JJ; Ros F; Aubá M; Errasti T; Olartecoechea B; Ruiz-Zambrana Á; Alcázar JL
    Ultrasound Obstet Gynecol; 2019 May; 53(5):693-700. PubMed ID: 30353585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the IOTA ADNEX model combined with HE4 for identifying early-stage ovarian cancer.
    Yang S; Tang J; Rong Y; Wang M; Long J; Chen C; Wang C
    Front Oncol; 2022; 12():949766. PubMed ID: 36185223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.